Published: Jun 09, 2021
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE)
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16
th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below.
Poster Presentation Title
: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies
Abstract Book Number: 236
Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CEST
Lead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia
Australia
Nedlands
Western-australia
Chany-cheah
Linkedin
International-congress-on-malignant-lymphoma
Department-of-haematology
Josep-carreras-leukaemia-research-institute
Nasdaq
University-of-western-australia
Exchange-commission